Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $474.0 million.

  • 10x Genomics' Cash & Equivalents rose 3775.4% to $474.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $474.0 million, marking a year-over-year increase of 3775.4%. This contributed to the annual value of $474.0 million for FY2025, which is 3775.4% up from last year.
  • 10x Genomics' Cash & Equivalents amounted to $474.0 million in Q4 2025, which was up 3775.4% from $432.5 million recorded in Q3 2025.
  • In the past 5 years, 10x Genomics' Cash & Equivalents registered a high of $622.0 million during Q2 2021, and its lowest value of $219.7 million during Q4 2022.
  • Over the past 5 years, 10x Genomics' median Cash & Equivalents value was $368.2 million (recorded in 2023), while the average stood at $397.8 million.
  • Per our database at Business Quant, 10x Genomics' Cash & Equivalents skyrocketed by 8301.49% in 2021 and then tumbled by 6259.31% in 2022.
  • Over the past 5 years, 10x Genomics' Cash & Equivalents (Quarter) stood at $587.4 million in 2021, then plummeted by 62.59% to $219.7 million in 2022, then soared by 63.5% to $359.3 million in 2023, then dropped by 4.24% to $344.1 million in 2024, then soared by 37.75% to $474.0 million in 2025.
  • Its Cash & Equivalents stands at $474.0 million for Q4 2025, versus $432.5 million for Q3 2025 and $397.7 million for Q2 2025.